uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, has announced the acquisition of InoCard GmbH, an innovative, early-stage biotechnology company focused on the development of gene therapy approaches for cardiac disease. InoCard has developed a novel gene therapy to preclinical proof of concept, for the one-time treatment of congestive heart failure (CHF), a rapidly progressing disease affecting 26 million people worldwide. InoCard founders Prof. Patrick Most and Prof. Hugo Katus will join uniQure as Managing Director of uniQure in Germany and Chairman of the Scientific Advisory Board, for Cardiovascular Diseases, respectively. Dechert’s Frankfurt-based corporate team of partner Dr. Rudiger Herrmann, National Partner Jochen Eimer and associate Dr. Monika Richter represented uniQure on this matter.